Deciphering the role of Ki67: prognostic insights in advanced breast cancer therapy with Cyclin-dependent kinase 4/6 inhibitors
Abstract Background Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are the standard of care in advanced breast cancer. While Ki67 is prognostic in early-stage disease, including adjuvant CDK4/6i, its role in metastatic setting is unclear. This study assessed Ki67’s prognostic value in advanced bre...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , , , , , , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
BMC
2026-02-01
|
| سلاسل: | BMC Cancer |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://doi.org/10.1186/s12885-026-15594-2 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
